COMMUNIQUÉS West-GlobeNewswire

Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2018
18/12/2018
CRANBURY, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported financial results and business highlights for its fiscal year ended September 30, 2018. Recent [...]
Imprivata Launches EPCS Ready, a Comprehensive Online Hub for Achieving National and State EPCS Compliance
18/12/2018
National bill requires e-prescribing for controlled substances under Medicare Part D by 2021 LEXINGTON, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Imprivata ® , the healthcare IT security company, today launched EPCS [...]
PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company
18/12/2018
Oslo (Norway), 18 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma [...]
BELLUS Health Closes $35M Financing to Support Development of its Lead Drug Candidate BLU-5937 for Chronic Cough
18/12/2018
Financing led by OrbiMed with Appointment of Mr. Chau Q. Khuong to BELLUS Board of Directors LAVAL, Quebec, Dec. 18, 2018 (GLOBE NEWSWIRE) -- BELLUS Health Inc. (TSX: BLU) (“BELLUS Health” or the “Company”), a clinical- [...]
BELLUS Santé complète un financement de 35 millions $ pour soutenir le développement de son médicament candidat phare, le BLU-5937 pour le traitement de la toux chronique
18/12/2018
OrbiMed a été le principal souscripteur du financement et M. Chau Q. Khuong a été nommé au conseil d'administration de BELLUS LAVAL, Québec, 18 déc. 2018 (GLOBE NEWSWIRE) -- BELLUS Santé inc. (TSX : BLU) (« BELLUS Santé [...]
Medigus in Advanced Negotiations to License its MUSE™ Technology
18/12/2018
OMER, Israel, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and a leader in direct visualization technology, today [...]
Nemaura Medical Announces Pricing of Up to $2.5 Million Public Offering
18/12/2018
LOUGHBOROUGH, England. Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® as a non-invasive affordable and flexible Continuous Glucose Monitor (CGM) for use by people with diabetes [...]
Agritek Holdings, Inc. Announces Filing Of Quarterly Report Ending September 30th 2018, Return To Fully Reporting Status, And Favorable Settlement Of Arbitration
18/12/2018
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Agritek Holdings, Inc. (OTC PINK: AGTK) www.AgritekHoldings.com , a fully integrated, active real estate investor for the cannabis sector in the [...]
Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia
18/12/2018
Expands lead product candidate’s development potential in rare cholestatic liver diseases Provides 10 years market exclusivity upon approval plus 2 years upon completion of PIP BOSTON, Dec. 18, 2018 (GLOBE NEWSWIRE) -- [...]
Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
18/12/2018
NEW YORK, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today [...]
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer
18/12/2018
CAMBRIDGE, Mass., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Anchiano Therapeutics ( TASE: ANCN ), a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat cancer, today [...]
Wiz Khalifa Partners with Supreme to Expand Cannabis Brand -- CFN Media
18/12/2018
SEATTLE, Dec. 18, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an [...]
Crown Bioscience Creates Center of Excellence for Bioinformatics, Big Data, and Biomarker Discovery Services
18/12/2018
Services and Capacity Increase with New Site Opening SAN DIEGO, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance [...]
Assure Holdings Performs First Neuromonitoring Case in Michigan
18/12/2018
Assure Continues Expansion, Now Operating in Six States DENVER, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (TSXV: IOM; OTCPK: ARHH), a provider of intraoperative [...]
Portola Pharmaceuticals to Webcast Corporate Update on January 8, 2019
18/12/2018
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and chief executive officer, will provide a corporate [...]
2018 Farm Bill Nears Passage For Hemp Based CBD Products Creating Tremendous Opportunity For PSIQ
18/12/2018
PSIQ POSITIONED TO SUBSTANTIALLY EXPAND ITS HEMP BASED CBD OPERATION WITH THE PASSAGE OF THE 2018 FARM BILL PSIQ SEEKS TO JUMP TO THE TOP TIER OF HEMP BASED CBD COMPANIES WITH THE PASSAGE OF THE 2018 FARM BILL SUNRISE, [...]
Cynata Completes Clinical Study Report for Phase 1 Trial of CYP-001 in GvHD
18/12/2018
MELBOURNE, Australia, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specializing in cell therapeutics, is pleased to announce that the clinical study [...]
Agile Therapeutics to Present at Biotech Showcase 2019
18/12/2018
PRINCETON, N.J., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced today that its Chairman and Chief Executive Officer, Al Altomari will present at the [...]
Palvella Therapeutics Announces $10 Million in Funding from Ligand Pharmaceuticals to Accelerate PTX-022 through Phase 2/3 Clinical Study in Pachyonychia Congenita
18/12/2018
Fast Track-Designated Program Commencing Phase 2/3 Study in Q1 2019 Wayne, PA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a rare disease biopharmaceutical company focused on developing and [...]

Pages